Inactive Instrument
Norda ASA Share Price Oslo Bors
Stocks
NORD
NO0010285190
Biotechnology & Medical Research
| Market Cap | 513M 54.49M 47.46M 44.92M 40.81M 76.24M 5.22B 76.62M 535M 207M 2.65B 205M 200M 8.49B | P/E 2023 * |
-
| P/E 2024 | 3.26x |
|---|---|---|---|---|---|
| Enterprise Value | 264M 28.07M 24.45M 23.14M 21.02M 39.27M 2.69B 39.47M 276M 107M 1.37B 105M 103M 4.37B | EV / Sales 2023 |
-1.24x | EV / Sales 2024 | 0.4x |
| Free-Float |
6.26% | Yield 2023 * |
-
| Yield 2024 | 32.5% |
| 04-09 | Exercise of Warrants by primary insiders | AQ |
| 10/07/25 | Mandatory Notification of Trade | AQ |
| 04/06/25 | Ocean Sun: Mandatory notification of trade | AQ |
| 27/03/25 | Nykode Therapeutics - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | AQ |
| 03/03/25 | Notification of trade | AQ |
| 1 day | +3.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
Frode Westvold
CEO | Chief Executive Officer | - | 07/04/2013 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 30/01/2014 | |
| Director/Board Member | 68 | 19/06/2013 | |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.37% | -6.12% | - | - | 47.19M | ||
| +1.23% | +1.87% | -0.15% | +9.57% | 45.91B | ||
| +0.23% | +4.72% | +44.32% | +27.27% | 44.25B | ||
| +0.52% | -3.15% | +349.53% | +520.09% | 41.99B | ||
| +1.55% | +3.41% | +6.40% | +76.45% | 39.58B | ||
| +1.75% | -0.28% | +12.42% | +41.11% | 31.08B | ||
| -0.20% | +5.49% | +23.57% | +119.72% | 17.21B | ||
| -3.49% | -8.49% | - | - | 16.27B | ||
| +2.92% | +8.40% | +22.46% | +38.87% | 14.96B | ||
| -2.45% | +2.41% | -3.16% | -35.16% | 13.42B | ||
| Average | +0.54% | +0.77% | +56.93% | +99.74% | 29.41B | |
| Weighted average by Cap. | +0.59% | +0.33% | +72.35% | +120.61% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 86.92M 9.23M 8.04M 7.61M 6.91M 12.91M 884M 12.98M 90.62M 35.04M 449M 34.67M 33.9M 1.44B | 372M 39.48M 34.39M 32.55M 29.57M 55.24M 3.78B 55.52M 388M 150M 1.92B 148M 145M 6.15B |
| Net income | 31.17M 3.31M 2.88M 2.73M 2.48M 4.63M 317M 4.65M 32.5M 12.57M 161M 12.43M 12.16M 516M | 126M 13.37M 11.65M 11.02M 10.02M 18.71M 1.28B 18.8M 131M 50.77M 651M 50.24M 49.12M 2.08B |
| Net Debt | -311M -33.05M -28.78M -27.24M -24.75M -46.24M -3.16B -46.47M -324M -125M -1.61B -124M -121M -5.15B | -249M -26.42M -23.01M -21.78M -19.79M -36.97M -2.53B -37.15M -259M -100M -1.29B -99.25M -97.04M -4.12B |
Employees
-
















